Quest rolls out new tests to assess breast cancer risk; Stanford scientists develop molecular imaging tech for bladder cancer detection;

> Quest Diagnostics ($DGX) is rolling out BRCAvantage Plus, the company's new suite of lab-developed tests for determining genetic breast cancer risk. Release

> Scientists at Stanford are developing an innovative molecular imaging technology that could improve bladder cancer detection and provide an alternative to standard endoscopy procedures. Release

> Researchers at the National Institutes of Health unveiled a new blood test that measures brain insulin resistance as an indicator of early-onset Alzheimer's disease. Release

> Charles River Laboratories ($CRL) acquired Cleveland, OH-based ChanTest in an all-cash transaction. Release

> Cleveland Clinic researchers are planning to use IBM's ($IBM) Watson technology to help oncologists uncover more personalized treatment options for cancer patients. Release

> French diagnostic outfit Genclis presented promising first clinical data for its molecular diagnostic test for nonmetastatic, triple-negative breast cancer. Release

> Clinical diagnostic firm Bio-Rad Laboratories agreed to shell out $55 million to settle foreign bribery allegations. Story (sub. req.)

Suggested Articles

Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data.

Saga Diagnostics has raised 40 million Swedish kronor, or about $4.1 million, to help develop its ultrasensitive cancer liquid biopsy tests.

Terumo will help Orchestra BioMed develop its sirolimus-eluting balloon in both coronary and peripheral cardiovascular interventions.